[Form 4] CHAMPIONS ONCOLOGY, INC. Insider Trading Activity

Rhea-AI Filing Summary

Champions Oncology (CSBR) CEO and director Robert L. Brainin received several option grants to buy common stock at an exercise price of $7.80 per share on July 16, 2025, expiring on July 16, 2035.

The awards include time-based vesting, where 25% vests on July 16, 2026 and the rest monthly over three years, plus multiple performance-based tranches. These performance options vest only if the company reaches EBITDA of $25 million or $35 million over any four-quarter period, achieves data revenue of $15 million or $30 million over any four-quarter period, or maintains a 45‑day average stock price at or above strike prices of $16.00 and $24.00.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Brainin Robert Lawrence

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase Common Stock	225,000	$7.80	$1.75M
Grant/Award	Option to purchase Common Stock	62,500	$7.80	$488K
Grant/Award	Option to purchase Common Stock	62,500	$7.80	$488K
Grant/Award	Option to purchase Common Stock	150,000	$7.80	$1.17M
Grant/Award	Option to purchase Common Stock	100,000	$7.80	$780K
Grant/Award	Option to purchase Common Stock	100,000	$7.80	$780K

Holdings After Transaction: Option to purchase Common Stock — 299,163 shares (Direct)

Footnotes (1)

1. The options vest and become exercisable as follows: 25% will vest on the one-year anniversary of the grant date on July 16, 2026; the balance will vest ratably at a rate of 1/36th each month thereafter. The options will vest and be exercisable if the Company achieves EBITDA of $25 million over any consecutive four quarter period (based on the Company's fiscal year). The options will vest and be exercisable when $15 million of the Company's data revenue is recognized over any consecutive four quarter period (based on the Company's fiscal year). The options will vest and be exercisable if (i) the Company achieves EBITDA of $35 million over any consecutive four quarter period (based on the Company's fiscal year) or (ii) when $30 million of the Company's data revenue is recognized over any consecutive four quarter period (based on the Company's fiscal year). The options will vest and be exercisable on the first date on which the average closing price (rounded to the nearest penny) of the Company's listed stock for the then previous forty five (45) calendar days is equal to or greater than the $16.00 Strike Price. The options will vest and be exercisable on the first date on which the average closing price (rounded to the nearest penny) of the Company's listed stock for the then previous forty five (45) calendar days is equal to or greater than the $24.00 Strike Price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brainin Robert Lawrence

(Last) (First) (Middle)

C/O CHAMPIONS ONCOLOGY, INC

ONE UNIVERSITY PLAZA, SUITE 307

(Street)

HACKENSACK NJ 07601

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CHAMPIONS ONCOLOGY, INC. [ CSBR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase Common Stock	$7.8	07/16/2025		A		225,000		(1)	07/16/2035	Common Stock	225,000	$7.8	299,163	D
Option to purchase Common Stock	$7.8	07/16/2025		A		62,500		(2)	07/16/2035	Common Stock	62,500	$7.8	361,663	D
Option to purchase Common Stock	$7.8	07/16/2025		A		62,500		(3)	07/16/2035	Common Stock	62,500	$7.8	424,163	D
Option to purchase Common Stock	$7.8	07/16/2025		A		150,000		(4)	07/16/2035	Common Stock	150,000	$7.8	574,163	D
Option to purchase Common Stock	$7.8	07/16/2025		A		100,000		(5)	07/16/2035	Common Stock	100,000	$7.8	674,163	D
Option to purchase Common Stock	$7.8	07/16/2025		A		100,000		(6)	07/16/2035	Common Stock	100,000	$7.8	774,163	D

Explanation of Responses:

1. The options vest and become exercisable as follows: 25% will vest on the one-year anniversary of the grant date on July 16, 2026; the balance will vest ratably at a rate of 1/36th each month thereafter.

2. The options will vest and be exercisable if the Company achieves EBITDA of $25 million over any consecutive four quarter period (based on the Company's fiscal year).

3. The options will vest and be exercisable when $15 million of the Company's data revenue is recognized over any consecutive four quarter period (based on the Company's fiscal year).

4. The options will vest and be exercisable if (i) the Company achieves EBITDA of $35 million over any consecutive four quarter period (based on the Company's fiscal year) or (ii) when $30 million of the Company's data revenue is recognized over any consecutive four quarter period (based on the Company's fiscal year).

5. The options will vest and be exercisable on the first date on which the average closing price (rounded to the nearest penny) of the Company's listed stock for the then previous forty five (45) calendar days is equal to or greater than the $16.00 Strike Price.

6. The options will vest and be exercisable on the first date on which the average closing price (rounded to the nearest penny) of the Company's listed stock for the then previous forty five (45) calendar days is equal to or greater than the $24.00 Strike Price.

Remarks:

	/s/ Robert L. Brainin	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.